REQUEST A DEMO
Total
USD $0.00
Search more companies

PT Merapi Utama Pharma (Indonesia)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: PT Merapi Utama Pharma Profile Updated: February 28, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

PT Merapi Utama Pharma is engaged in pharmaceutical manufacturing and trading. The Company started its commercial operations in 1968 and has 33 branches.

Headquarters
Kota Jakarta Pusat Cikini Menteng Dki Jakarta
Central Jakarta; Jakarta; Postal Code: 10330

Contact Details: Purchase the PT Merapi Utama Pharma report to view the information.

Website: http://www.merapi.net

Basic Information
Total Employees:
Purchase the PT Merapi Utama Pharma report to view the information.
Outstanding Shares:
Purchase the PT Merapi Utama Pharma report to view the information.
Registered Capital:
Purchase the PT Merapi Utama Pharma report to view the information.
Financial Auditors:
Purchase the PT Merapi Utama Pharma report to view the information.
Incorporation Date:
May 01, 1968
Key Executives
Purchase this report to view the information.
President Director
Purchase this report to view the information.
President Commissioner
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after PT Merapi Utama Pharma report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Net sales revenue
13.59%
Total operating revenue
13.59%
Total assets
12.53%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?